following a second resubmission assessed under the orphan medicine process:
carfilzomib (Kyprolis®) is accepted for restricted use within NHSScotland.
Indication under review: in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
SMC restriction: for patients who have received only one prior therapy.
Carfilzomib in combination with lenalidomide and dexamethasone improved progression free survival and overall survival compared with lenalidomide and dexamethasone in adults with relapsed and / or refractory multiple myeloma who had received one to three prior therapies.
This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
- Medicine name:
- carfilzomib (Kyprolis)
- SMC ID:
In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
- Pharmaceutical company
- Amgen Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published
- 12 October 2020